our people

Ventria Board

Board of Directors

William W. Crouse
Mr. Crouse is a retired Managing General Partner of Healthcare Ventures, which led the strategic development and management of more than 100 companies with a combined market capitalization exceeding $60 billion.  Examples of HealthCare Ventures companies include Human Genome Sciences, MedImmune (acquired by Astra Zeneca), Novazyme (acquired by Genzyme), Shire, Dendreon, and FoldRx, (acquired by Pfizer).  Prior to joining HealthCare Ventures, he was Worldwide President of Ortho Diagnostic Systems and a Vice President of Johnson & Johnson International from 1987 to 1993. He currently serves on the Board of Directors for The Medicines Company, and 3 private biotech companies. He also serves as an Advisory Board Member of Windham Venture Partners.

Scott E. Deeter
Mr. Deeter has served as the Company’s Chief Executive Officer since it was formed in 2001. He licensed technology from University of California that provided the scientific foundation for the ExpressTec platform for recombinant protein expression. Previously, he started and led a joint venture between Cargill and F. Hoffmann-La Roche that commercialized pharmaceutical intermediates and functional food ingredients derived from plants. He served as President and CEO of CyberCrop and was a member of the Technology and Life Sciences Group of Salomon Brothers. He is a graduate of the University of Kansas, University of Chicago, and London School of Economics and Political Science.

William H. Rutter, Esq.,
Mr. Rutter is an entrepreneur who has successfully developed a series of companies in diverse businesses including beverages, restaurants, and brew pubs. He formerly practiced law with the Denver, Colorado firm of Sherman & Howard. He also is President of Moab Music Festival, Inc. a 501(c)(3) charitable organization that produces a chamber music festival each year in Moab, Utah.

William J. Rutter, PhD
Dr. Rutter is Chairman and CEO of Synergenics, LLC. Previously, Dr. Rutter cofounded Chiron Corporation (now part of Novartis) and served as its Executive Chairman until 1999. He served as Chairman of the Department of Biochemistry at UCSF from 1969-1982, and head of the Hormone Research Institute from 1982-1989. His lab is recognized for contributions to development of recombinant DNA technologies and some of its early achievements, including the cloning of the insulin gene and the development of a vaccine for hepatitis B. He is a member of the U.S. National Academy of Sciences and the American Academy of Arts and Sciences. He has received numerous honors including the Heinz Award; the Bower Award and Prize for Achievement in Science from the Franklin Institute; and the Biotechnology Heritage Award.